Loading…
Quantum BioPharma Ltd. is projected to rise to $3.41 by 2027, a +12% move from its current price of $3.05. QNTM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.93 | $3.05 | $3.18 | +0.01% |
| Aug 6 | $2.88 | $3.05 | $3.23 | +0.01% |
| Aug 7 | $2.84 | $3.05 | $3.27 | +0.02% |
| Aug 8 | $2.81 | $3.05 | $3.31 | +0.02% |
| Aug 9 | $2.78 | $3.05 | $3.34 | +0.03% |
| Aug 10 | $2.76 | $3.05 | $3.37 | +0.03% |
| Aug 11 | $2.74 | $3.05 | $3.40 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.74 | $3.05 | $3.40 | +0.04% |
| Week 2 | $2.62 | $3.05 | $3.56 | +0.07% |
| Week 3 | $2.53 | $3.05 | $3.68 | +0.11% |
| Week 4 | $2.46 | $3.05 | $3.79 | +0.14% |
| Week 5 | $2.40 | $3.06 | $3.89 | +0.18% |
| Week 6 | $2.35 | $3.06 | $3.98 | +0.21% |
| Week 7 | $2.30 | $3.06 | $4.07 | +0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quantum BioPharma Ltd. is a biopharmaceutical company that operates through two segments: Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse.
In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.
Quantum BioPharma Ltd. (QNTM) is a healthcare asset with a current price of $3.04. It carries a market capitalization of $19.45M and is ranked 4593 by market cap.
The stock’s price outlook reflects a pathway of gradual movement higher over the forecast horizon, with the average in 2026 at $3.04 and longer-term upside indicated into the 2030s and beyond, including a 2050 average of $10.11 and a 2050 max of $23.25.
Overall, near-term price action shows limited upside potential relative to the current price, while the longer-term forecast projects meaningful upside as late as the 2030s and 2040s, consistent with a bullish longer-term trajectory.
A major floor 30.6% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 28.9% above — a clean break opens room to run.
A major ceiling 203.0% above — clearing it would confirm fresh momentum.
Key QNTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.91 | Buy | $2.90 | Buy |
| MA 10 | $2.93 | Buy | $2.97 | Buy |
| MA 20 | $3.15 | Sell | $3.18 | Sell |
| MA 50 | $4.17 | Sell | $3.75 | Sell |
| MA 100 | $4.14 | Sell | $4.49 | Sell |
| MA 200 | $5.93 | Sell | $6.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.67 | Neutral |
| Stoch RSI (14) | 45.41 | Neutral |
| CCI (20) | -77.61 | Neutral |
| Williams %R (14) | -90.91 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | -15.00 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 9.09 | Buy |
| TRIX (15) | -1.31 | Sell |
| Awesome (5,34) | -0.49 | Sell |
| Ultimate (7,14,28) | 42.48 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 2.86 | Buy |
| ADX (14) | 27.49 | Sell |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is Neutral.
RSI14 is 30, and the stock’s price is trading below key moving averages, with SMA50 at $4.70 and SMA200 at $6.55. Support is listed at $3.04 and resistance at $4.26. The 30-day price range extends from a low of $2.20 to a high of $4.19.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.10 | $3.05 | $3.91 | 0% | Neutral | |
| $2.60 | $3.41 | $4.80 | +12% | Neutral | |
| $2.58 | $3.55 | $5.26 | +16% | Neutral | |
| $2.48 | $3.53 | $5.46 | +16% | Neutral | |
| $2.10 | $3.09 | $4.93 | +1% | Neutral | |
| $2.14 | $3.26 | $5.36 | +7% | Neutral | |
| $2.43 | $3.80 | $6.42 | +25% | Bullish | |
| $2.65 | $4.27 | $7.37 | +40% | Bullish | |
| $3.03 | $5.00 | $8.82 | +64% | Bullish | |
| $2.91 | $4.93 | $8.87 | +62% | Bullish | |
| $3.76 | $7.18 | $14.01 | +135% | Bullish | |
| $4.50 | $10.00 | $21.88 | +228% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.10 | $3.05 | $3.75 | +0.00% |
| September 2026 | $2.50 | $3.00 | $3.73 | -1.69% |
| October 2026 | $2.53 | $3.06 | $3.87 | +2.19% |
| November 2026 | $2.57 | $3.14 | $4.01 | +2.42% |
| December 2026 | $2.45 | $3.02 | $3.91 | -3.77% |
Click any year to see its month-by-month QNTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The QNTM price prediction for 2026 points to an average of $3.05 (low $2.10, high $3.91) — a potential gain of 0% on today's $3.05. A consolidation phase looks the most probable path here.
In 2027, QNTM is projected to trade between $2.60 and $4.80, averaging $3.41 — a potential gain of +12% from today's $3.05. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
Quantum BioPharma Ltd.'s 2028 outlook centres on $3.55, within a $2.58 to $5.26 range. That is up +4% on the projected 2027 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, QNTM could reach as high as $5.46, with a base case around $3.53 and support toward $2.48 — roughly +16% from $3.05. Price action looks broadly range-bound.
Expect QNTM to range from $2.10 to $4.93 through 2030. The $3.09 average target implies a +1% move from current prices. That is -13% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The QNTM price prediction for 2031 points to an average of $3.26 (low $2.14, high $5.36) — a potential gain of +7% on today's $3.05. Price action looks broadly range-bound.
In 2032, QNTM is projected to trade between $2.43 and $6.42, averaging $3.80 — a potential gain of +25% from today's $3.05. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Quantum BioPharma Ltd.'s 2033 outlook centres on $4.27, within a $2.65 to $7.37 range. That is up +12% on the projected 2032 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2034, QNTM could reach as high as $8.82, with a base case around $5.00 and support toward $3.03 — roughly +64% from $3.05. Buyers look set to stay in control over this stretch.
Expect QNTM to range from $2.91 to $8.87 through 2035. The $4.93 average target implies a +62% move from current prices. That is -1% versus the projected 2034 average. Momentum favours further upside here.
The QNTM price prediction for 2040 points to an average of $7.18 (low $3.76, high $14.01) — a potential gain of +135% on today's $3.05. Buyers look set to stay in control over this stretch.
In 2050, QNTM is projected to trade between $4.50 and $21.88, averaging $10.00 — a potential gain of +228% from today's $3.05. That is up +39% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in QNTM today (≈ 327.868852 QNTM) could be worth
$3,278.09
+$2,278.09 (+228%) by 2050 · US Dollar
Based on the average projected QNTM price of $10 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNTMwould be worth at today's price.
$1,000 invested in QNTM on Jul 31, 2025 (≈ 42.607585 QNTM) would be worth
$129.95
-$870.05 (-87.0%) today · 0.13× · US Dollar
Based on a QNTM entry price of $23.47 vs. today's $3.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.99 | $1,020.07 | +2.0% |
| 1 month ago | $3.36 | $907.74 | -9.2% |
| 3 months ago | $5.55 | $549.55 | -45.0% |
| 6 months ago | $4.24 | $719.34 | -28.1% |
| 1 year ago | $23.47 | $129.95 | -87.0% |
| All time (5.0y) ago | $109.85 | $27.77 | -97.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNTM forecast.
Our base-case forecast reaches $6.10 around 2040.
Implied market cap at $6.10: $39.03M
The multi-year forecast shows a bullish arc beginning in the 2030s, with higher average prices and sizable upside potential. In 2032 the average price is $3.88 and the max is $6.95, with a 27.6% ROI and bullish sentiment.
In 2033 the forecast average rises to $4.57 and the max to $8.40, with a 50.3% ROI and bullish sentiment. In 2034 the average is $5.20 and the max is $9.79, with an 71.1% ROI. In 2035 the average is $5.10 and the max is $9.81, with a 67.7% ROI and bullish sentiment.
By 2040 the average climbs to $7.83 and the max to $16.48, with a 157.7% ROI and bullish sentiment. By 2050 the average is $10.11 and the max is $23.25, with a 232.6% ROI and bullish sentiment. These outcomes assume continued development progress and favorable market conditions, but they are estimates and not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $1.98, avg $3.09, max $5.21; ROI 1.7; sentiment NEUTRAL.
Near-term forecasts show NEUTRAL through 2026–2029, while longer-term projections are bullish with substantial upside by 2032–2050 (e.g., max up to $23.25 in 2050 and ROI up to 232.6%). Current price is $3.04 and 2026–2029 averages are around the low $3s.
Yes. The forecast shows a max of $8.40 in 2033, then higher max values of $9.79 in 2034 and $9.81 in 2035.
The 2040 forecast shows an average of $7.83 with a max of $16.48 and a 157.7% ROI, with bullish sentiment.
Quantum BioPharma Ltd. Community Discussion
0Share your Quantum BioPharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.